コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 elop PfRH5 as an urgently needed blood-stage malaria vaccine.
2 del, including the soon-to-be licensed RTS,S malaria vaccine.
3 ly, is the leading candidate for a pregnancy malaria vaccine.
4 the leading candidate for a pre-erythrocytic malaria vaccine.
5 ble carrier system(s) for the development of malaria vaccine.
6 the chances of developing a highly effective malaria vaccine.
7 erably greater than that offered by the best malaria vaccine.
8 complicate efforts to develop a blood stage malaria vaccine.
9 potential as a component of a multi-antigen malaria vaccine.
10 s for the development of a P. falciparum GAP malaria vaccine.
11 y for the development of a live-vector-based malaria vaccine.
12 step in the development of a preerythrocytic malaria vaccine.
13 (42)) is a prime candidate for a blood-stage malaria vaccine.
14 n be used in the development of an effective malaria vaccine.
15 signed candidate sequence for inclusion in a malaria vaccine.
16 the safety and immunogenicity of the AMA1-C1 malaria vaccine.
17 ising new candidate for the development of a malaria vaccine.
18 a leading candidate for inclusion in a human malaria vaccine.
19 ntigen 1 (AMA1) is a leading candidate for a malaria vaccine.
20 a parasites brings us closer to an effective malaria vaccine.
21 d RAP2) are candidate antigens for a subunit malaria vaccine.
22 arly supports its inclusion in a multivalent malaria vaccine.
23 alciparum is a candidate protein for a human malaria vaccine.
24 mponent of a multivalent P. falciparum human malaria vaccine.
25 rtant candidate antigen for a multicomponent malaria vaccine.
26 further development of BVp42 as a candidate malaria vaccine.
27 the promise for a potent, broadly protective malaria vaccine.
28 implications in the development of a subunit malaria vaccine.
29 effective carrier for a PfMSP2-based subunit malaria vaccine.
30 , which could contribute to a cost-effective malaria vaccine.
31 s may aid in the design of a next-generation malaria vaccine.
32 underway to find an effective and affordable malaria vaccine.
33 further increased the need for an effective malaria vaccine.
34 l future development plan for the RTS,S/AS01 malaria vaccine.
35 suitable candidates for the development of a malaria vaccine.
36 EBA-175 as components in a combination of a malaria vaccine.
37 ), will likely be the first publicly adopted malaria vaccine.
38 topes to maximize the response to multistage malaria vaccines.
39 proteins as an effective platform to deliver malaria vaccines.
40 ve the protective efficacy of RTS,S or other malaria vaccines.
41 otection is unmatched by current recombinant malaria vaccines.
42 ould be important in informing the design of malaria vaccines.
43 shows promise for simple delivery of subunit malaria vaccines.
44 uation would be the development of effective malaria vaccines.
45 gn and test more efficacious next-generation malaria vaccines.
46 l prove critical in the search for effective malaria vaccines.
47 tage protection by candidate preerythrocytic malaria vaccines.
48 nformation may aid in the rational design of malaria vaccines.
49 nt implications for development of effective malaria vaccines.
50 struct genetically modified, live attenuated malaria vaccines.
51 ign of Plasmodium falciparum live attenuated malaria vaccines.
52 most promising candidates for development as malaria vaccines.
53 t for exploiting GPIs for the development of malaria vaccines.
54 e required for the development of successful malaria vaccines.
55 ntifying target antigens for preerythrocytic malaria vaccines.
56 rotective immunity to exo-erythrocytic stage malaria vaccines.
57 parasite, and has been used for making anti-malaria vaccines.
58 gens is therefore warranted in the design of malaria vaccines.
59 mportant component of pre-erythrocytic human malaria vaccines.
60 tructure-based design of next-generation CSP malaria vaccines.
61 ing adjunctive therapies and next-generation malaria vaccines.
62 egy in the development of highly efficacious malaria vaccines.
63 from the first clinical trials of candidate malaria vaccines?
64 hase I dose and route finding study of a new malaria vaccine, a replication-incompetent chimpanzee ad
65 e examined the MBC response to two candidate malaria vaccines administered with or without CpG, a TLR
66 partial efficacy of RTS,S/AS01 - the leading malaria vaccine against P. falciparum (Pf) - has been as
68 meet this challenge, including an effective malaria vaccine and adequate vector control strategies.
70 alleles before and after vaccination in the malaria vaccine and control groups and examination of th
71 Large-scale functional genomics studies for malaria vaccine and drug development will depend on the
72 ncing the efficacy of a whole parasite-based malaria vaccine and for designing strategies for the dev
73 ssessed the cross-protective efficacy of the malaria vaccine and inferred which polymorphic amino aci
74 candidate molecule for inclusion in a human malaria vaccine and is strongly conserved in the genus.
75 in the development of an AMA-1 antigen-based malaria vaccine and may also guide testing of AMA-1-base
76 potent public antibody clonotype, advancing malaria vaccine and prophylactic antibody development.
77 veral candidate vaccines including the RTS,S malaria vaccine and the subunit glycoprotein E varicella
78 order to define the protective efficacy of a malaria vaccine and thus guide programmatic decisions on
79 l in the development of a multispecies human malaria vaccine and vaccines against other infectious di
80 who were receiving RTS,S/AS01 or RTS,S/AS02 malaria vaccine and were undergoing experimental challen
83 lly as an adjuvant in cancer, hepatitis, and malaria vaccines and in allergen-specific immunotherapy.
84 e to "50 by 50." A decade ago, there were no malaria vaccines and the only available tuberculosis vac
85 iological and immunological requirements for malaria vaccines and the recent history of malaria vacci
87 al. strengthens the case for prime-and-trap malaria vaccines and will greatly aid further investigat
89 elated anonymous protein (TRAP), a candidate malaria vaccine antigen, is required for Plasmodium spor
92 a emerging from the first phase 3 trial of a malaria vaccine are raising hopes that a licensed vaccin
93 s well as during immunization with candidate malaria vaccines are summarized and related to each othe
94 A-175, as one component of a ligand-blocking malaria vaccine, are largely unaffected by polymorphism
95 We have designed and produced a prototypic malaria vaccine based on a highly versatile self-assembl
96 inical testing of a multistage, multiantigen malaria vaccine based on DNA plasmid immunization techno
97 n as TRAP, is included in experimental human malaria vaccines because Plasmodium yoelii SSP2 is the t
98 ion is used to measure efficacy of candidate malaria vaccines before field studies are undertaken.
99 orrelate of protective immunity to the RTS,S malaria vaccine, but few descriptions of the natural var
100 R2CSA is a leading candidate for a pregnancy malaria vaccine, but its large size ( approximately 350
101 as another leading candidate for an asexual malaria vaccine, but without any direct in vivo evidence
102 velopers now moves to the next generation of malaria vaccines, but it is not yet clear what character
103 these obstacles, we constructed an Ad-based malaria vaccine by inserting a B cell epitope derived fr
105 emonstrate that a multicomponent, multistage malaria vaccine can induce immune responses that inhibit
106 ur data suggest that recombinant blood stage malaria vaccines can drive the evolution of more virulen
110 Merozoite surface protein-1 (MSP1), a prime malaria vaccine candidate and one of the most abundant c
111 Apical membrane antigen 1 (AMA1) is a key malaria vaccine candidate and target of neutralizing ant
112 inhibitory activity, bound to the important malaria vaccine candidate antigen, Plasmodium falciparum
113 induced by immunization with two blood-stage malaria vaccine candidate antigens, apical membrane anti
119 I trial, an alum formulation of ICC-1132, a malaria vaccine candidate comprising hepatitis B core (H
120 hese studies support ICC-1132 as a promising malaria vaccine candidate for further clinical testing u
121 Following over two decades of research, the malaria vaccine candidate RTS,S has reached the final st
125 pical membrane antigen 1 (AMA1) is a leading malaria vaccine candidate that possesses polymorphisms t
127 use of impregnated bed nets, we developed a malaria vaccine candidate with the aim of reducing seque
128 ace protein1 (MSP1) is a leading blood-stage malaria vaccine candidate, and anti-MSP1 antibodies from
129 riant surface antigen VAR2CSA is a pregnancy malaria vaccine candidate, but its size and polymorphism
131 to assess the safety and immunogenicity of a malaria vaccine candidate, ICC-1132 (Malarivax), compose
132 though CSP has been extensively studied as a malaria vaccine candidate, little is known about its str
134 een generated that secrete into their milk a malaria vaccine candidate, the 42-kDa C-terminal portion
140 on genetically attenuated parasites both as malaria vaccine candidates and also as valuable tools to
142 production and suboptimal immunogenicity of malaria vaccine candidates have slowed the development o
145 urface protein 1 (MSP1) is among the leading malaria vaccine candidates that target infection by asex
146 e to express three different AMA1-DiCo-based malaria vaccine candidates to develop a vaccine cocktail
147 tage antigens, to support the development of malaria vaccine candidates, and to search for immunologi
154 denovirus (Ad) serotype 5 has been tested in malaria vaccine clinical trials with excellent safety pr
155 that the further development of PfMSP8 as a malaria vaccine component should focus on the use of PfM
160 ply on the public health impact of the RTS,S malaria vaccine could be reduced by introducing the vacc
163 , AMA-1, is a component of several candidate malaria vaccines currently in various stages of trials i
170 r malaria vaccines and the recent history of malaria vaccine development and then put forward a manif
171 MI) has supported Plasmodium falciparum (Pf) malaria vaccine development by providing preliminary est
176 plexity of the malaria parasite has made the malaria vaccine development process tenuous, advances in
181 on for an approach to pre-erythrocytic-stage malaria vaccine development, based on the induction of p
182 rasite Plasmodium yoelii (Py) as a model for malaria vaccine development, we have previously shown th
200 us ChAd63 are promising delivery systems for malaria vaccines due to their safety profiles and proven
201 oites, we have constructed candidate subunit malaria vaccines expressing six preerythrocytic antigens
202 ortant consideration in the development of a malaria vaccine for individuals living in areas of endem
203 es as economical, safe, and readily produced malaria vaccines for the one-third of the world's popula
204 administration of three doses of RTS,S/AS01 malaria vaccine given at one-month intervals was inferio
205 t skin-based delivery of an adenovirus-based malaria vaccine, HAdV5-PyMSP1(4)(2), to mice using silic
210 sults from recent efficacy trials of HIV and malaria vaccines have instilled hope that another golden
212 fficacy of a single dose adenovirus-vectored malaria vaccine in a mouse model of malaria by co-admini
214 ontrol and elimination; however, the leading malaria vaccine in development, RTS,S/AS01, provided onl
215 nization with an attenuated whole sporozoite malaria vaccine in humans, significantly higher numbers
216 mains are incorporated in RTS,S, the leading malaria vaccine in phase 3 trials that, to date, protect
217 y of a precisely defined synthetic polyoxime malaria vaccine in volunteers of diverse HLA types.
232 development of a successful ligand-blocking malaria vaccine is the demonstration that antibodies ind
235 For development of a long-lasting protective malaria vaccine, it is crucial to understand whether Pla
236 Novel anti-adherence therapeutics and a malaria vaccine may derived from exploitation of the str
237 The disappointing efficacy of blood-stage malaria vaccines may be explained in part by allele-spec
239 Here, we used an attenuated whole parasite malaria vaccine model in humans and various experimental
241 There are at least 25 projects in the global malaria vaccine pipeline, as well as 47 medicines and 13
247 een as a major step forward on the road to a malaria vaccine rather than as arrival at the final dest
248 nical trials of new heterologous prime-boost malaria vaccine regimens using DNA, fowlpox or MVA, have
250 ment of an efficacious Plasmodium falciparum malaria vaccine remains a top priority for global health
252 ies to optimize formulations of multisubunit malaria vaccines require a basic knowledge of underlying
262 d immunogenic, the first such virosome-based malaria vaccine showed no protection in a Phase IIa clin
265 ren aged 6 weeks to 5 years participating in malaria vaccine studies in an area of high malaria and h
266 RTS,S/AS01E has been tested in a phase 3 malaria vaccine study with partial efficacy in African c
272 ome this problem for the leading blood-stage malaria vaccine targets, that is, merozoite surface prot
274 vaccines to maximize the efficacy of a human malaria vaccine that includes immunogenic regions of the
275 infection may be key to the development of a malaria vaccine that induces long-lived protection.
277 latform to develop an efficacious whole-cell malaria vaccine that prevents infection at the preerythr
278 , but the best hope for a highly efficacious malaria vaccine that would improve prospects for malaria
279 nities and challenges inherent in developing malaria vaccines that target the infected hepatocyte.
281 under way to improve the efficacy of subunit malaria vaccines through assessments of new adjuvants, v
287 serve as the primary end point in phase III malaria vaccine trials--the first of which will be held
288 is the standard assay to assess efficacy in malaria vaccines trials in endemic areas, it has poor an
290 in Tanzanian volunteers when an experimental malaria vaccine was adjuvanted in GLA-SE but not when fo
293 overcome challenges encountered with subunit malaria vaccines, we established that the use of highly
297 argue that rational design of more effective malaria vaccines will be accelerated by a better underst
298 t target populations for asexual blood-stage malaria vaccines will have been exposed to malaria paras